Clinical trials: Liver Inflammation
Hepatitis B
The Effect of an Electronic Medical Record (EMR) Alert on Hepatitis B Screening
Asian and Pacific Islander Americans at risk, but never tested for chronic hepatitis B have been randomized to receive an electronic alert in their electronic medical chart to remind primary care physicians to screen them for…
- Trial name
- NCT04240678
- Testing
- Electronic HBV Alert
- Volunteers
- 8,299 people
- Sponsor
- University of California, Davis
Chronic Hepatitis C
Neutrophil Function During Therapy With Protease Inhibitors in Chronic Hepatitis C
The aim of this study is to characterize neutrophil function in patients undergoing chronic hepatitis C triple therapy with protease inhibitors in comparison to dual therapy with peginterferon and ribavirin and with interferon…
- Trial name
- NCT02545335
- Where
- Austria
- Volunteers
- 174 people
- Sponsor
- Medical University of Graz
Hepatitis C
Safety, Pharmacokinetics, and Pharmacodynamics of MK-8876 in Participants With Hepatitis C Infection (MK-8876-003)
This adaptive design study will evaluate the safety, pharmacokinetics, and effect on hepatitis C virus (HCV) RNA levels of multiple doses of MK-8876 in participants with HCV infection.
- Trial name
- NCT01930058
- Testing
- MK-8876
- Volunteers
- 9 people
- Sponsor
- Merck Sharp & Dohme LLC
The Study Goal is to Assess the Introduction of Sustainable Family Planning/Reproductive Health Information and Services Through, Land O' Lakes-supported Dairy Cooperatives
Family Planning Through Dairy Cooperatives
This observational study will assess a model for providing family planning through quarterly events organized by dairy cooperatives supported by Land O'Lakes in Kenya.
- Trial name
- NCT01226433
- Where
- Kenya
- Volunteers
- 319 people, healthy volunteers welcome
- Sponsor
- FHI 360
Chronic Hepatitis B
Phase 2 Trial of Therapeutic Hepatitis B Vaccine (Mimogen-based) for Chronic Hepatitis B
The purpose is to evaluate efficacy and safety of therapeutic Hepatitis B Virus（HBV） vaccine (mimogen-based) treatment in chronic hepatitis B patients and to explore the most effective dosage and provide the rational for optimal…
- Trial name
- NCT00869778
- Testing
- εPA-44
- Where
- 15 sites in China
- Volunteers
- 360 people
- Sponsor
- Chongqing Jiachen Biotechnology Ltd.
Hepatitis C Virus Infection, Response to Therapy of
Effects of Activity and Education Program on Patients With Chronic Hepatitis C Infection
This 4-year project will be guided by a biobehavioral model for the study of exercise interventions in two phases with the purposes to : 1.
- Trial name
- NCT01572233
- Testing
- Personalized Physical Activity and Psycho-Education (PPAPE) Program
- Where
- Taiwan
- Volunteers
- 300 people
- Sponsor
- National Taiwan University Hospital
Severe Alcoholic Hepatitis
Efficacy of G-CSF in the Management of Steroid Non-responsive Severe Alcoholic Hepatitis
After successful screening, first the investigators first treat patients of severe alcoholic hepatitis with steroids for 7 days.
- Trial name
- NCT01820208
- Testing
- G-CSF
- Where
- India
- Volunteers
- 28 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Hepatitis C
Clinical Performance Evaluation of DxN HCV Assay
The DxN Hepatitis C Virus (HCV) Assay is an in vitro diagnostic assay intended as an aid in the management of of HCV-infected individuals undergoing antiviral therapy.
- Trial name
- NCT03125408
- Testing
- HCV Assay
- Where
- United States
- Volunteers
- 210 people
- Sponsor
- Beckman Coulter, Inc.
Hepatitis B
New Methods to Measure the Immune Response to Hepatitis B Vaccine
Hepatitis B vaccine is a safe and effective vaccine used widely throughout the world. Because of this it is a useful vaccine in which to develop new methods for studying immune responses.
- Trial name
- NCT01821547
- Testing
- Hepatitis B vaccine
- Where
- United Kingdom
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Inflammatory Bowel Disease (IBD), Hepatitis B Virus
Impact of Hepatitis B Virus on Inflammatory Bowel Disease
The goal of this observational retrospective study is to assess the impact of hepatitis B virus (HBV) infection on the clinical course and outcomes of inflammatory bowel disease (IBD) in Egyptian patients.
- Trial name
- NCT06881238
- Testing
- History of IBD course and outcome in HBV patients
- Where
- Egypt
- Volunteers
- 162 people
- Sponsor
- Tanta University
Hepatocellular Carcinoma, HBV
Impact of Hepatitis B Immunoglobulins in Patients With Chronic Hepatitis B on Hepatocellular Carcinoma - a Proof of Concept Study
In the current literature, infection with the hepatitis B virus (HBV) is described as one of the main risk factors for the development of hepatocellular carcinoma (HCC).
- Trial name
- HBIG (NCT05293158)
- Testing
- Hepatect CP 50 I.E./ml infusion solution
- Volunteers
- 5 people
- Sponsor
- Medical University of Graz
Hepatitis C
T Regulatory Cells in Hepatitis c Infected Patients
Chronic hepatitis C infection is a global worldwide health problem with an increasing burden year-by-year, particularly in areas with a high endemicity like Egypt .
- Trial name
- NCT03186235
- Testing
- Flow cytometry
- Where
- Egypt
- Volunteers
- 88 people
- Sponsor
- Assiut University
Chronic Hepatitis C
A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects
The purpose of this study is to evaluate the relative bioavailability, safety, and tolerability of 3 new formulations of telaprevir relative to the Incivek 375-mg tablets.
- Trial name
- NCT01511432
- Testing
- telaprevir formulation A, telaprevir Formulation B, telaprevir Formulation C
- Where
- 2 sites in United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated
Chronic HCV Infection
Antaitavir Hasophate Capsules Combined With Yiqibuvir Tablets in Treatment Adult Patients With Chronic Hepatitis C
The safety, tolerability and antiviral activity of Antaitavir Hasophate in Combination With Yiqibuvir in treatment-naive and treatment-experienced patients with chronic hepatitis C virus (HCV) infection
- Trial name
- NCT05395416
- Testing
- HEC74647PA+HEC110114
- Where
- 36 sites in China
- Volunteers
- 514 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Chronic Hepatitis C Infection
The Role of FGL2-FcgammaRIIB Inhibitory Pathway in Human Viral Hepatitis
Viral hepatitis is a serious world health problem affecting over 1 billion people worldwide. Presently the lack of highly effective treatments results in many patients requiring liver transplantation or death.
- Trial name
- NCT01711164
- Where
- Canada
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Chronic Hepatitis C
Pilot Comparison of Standard Antiviral Therapy With and Without 12 Weeks of Betaine in Genotype 1 Naive Patients
The primary purpose of the study is to compare the safety and effectiveness of standard treatment for chronic hepatitis C using peginterferon alpha-2a (Pegasys) and ribavirin (Copegus) to those same medications plus a dietary…
- Trial name
- NCT00571714
- Testing
- Peginterferon alpha-2a and ribavirin, Peginterferon alpha-2a , ribavirin and betaine
- Sponsor
- University of Nebraska
HIV Infections
Safety and Effectiveness of an Adjuvant in Improving Immune Response to Hepatitis B Virus Vaccine in HIV Infected Individuals
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a naturally occurring substance that is made by the body in response to infection or inflammation, and greatly improves cellular immune responses.
- Trial name
- NCT00272493
- Testing
- Hepatitis B virus vaccine with GM-CSF adjuvant, Hepatitis B virus vaccine
- Where
- 11 sites in United States
- Volunteers
- 48 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis Delta Virus
Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV
The Phase 3 LIMT-2 study will evaluate the safety and efficacy of Peginterferon Lambda treatment for 48 weeks with 24 weeks follow-up compared to no treatment for 12 weeks in patients chronically infected with HDV.
- Trial name
- LIMT-2 (NCT05070364)
- Testing
- Peginterferon Lambda-1a
- Where
- 48 sites in United States, Belgium and 10 more
- Volunteers
- 150 people
- Sponsor
- Eiger BioPharmaceuticals
Hepatitis C
An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus
The purpose of this study is to assess the safety, efficacy, and pharmacokinetics in a carefully monitored cohort of pediatric subjects infected with hepatitis C virus (HCV) on a telaprevir-based regimen in Part A and with dose…
- Trial name
- NCT01701063
- Testing
- Telaprevir, Peginterferon alfa-2b, Ribavirin
- Where
- 23 sites in United States, Belgium and 4 more
- Volunteers
- 42 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Hepatitis C, HIV Coinfection
Supporting Treatment Outcomes Among PWID
The goal of this study is to improve HCV care continuum outcomes for people who inject drugs (PWID), reduce potential onward transmission to others and improve HIV outcomes among those who are HIV/HCV coinfected.
- Trial name
- STOP-C (NCT04652804)
- Testing
- Low intensity HCV treatment adherence support, Medium intensity HCV treatment adherence support, High intensity HCV treatment adherence support
- Where
- India
- Volunteers
- 3,000 people
- Sponsor
- Johns Hopkins University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.